295 related articles for article (PubMed ID: 22293827)
1. Baseline susceptibility of primary HIV-2 to entry inhibitors.
Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
[TBL] [Abstract][Full Text] [Related]
2. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
3. HIV-2 susceptibility to entry inhibitors.
Borrego P; Taveira N
AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
5. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
6. Entry inhibitors in the treatment of HIV-1 infection.
Tilton JC; Doms RW
Antiviral Res; 2010 Jan; 85(1):91-100. PubMed ID: 19683546
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
9. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
10. CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1.
Heredia A; Gilliam B; DeVico A; Le N; Bamba D; Flinko R; Lewis G; Gallo RC; Redfield RR
AIDS; 2007 Jun; 21(10):1317-22. PubMed ID: 17545708
[TBL] [Abstract][Full Text] [Related]
11. Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
McKinnell JA; Saag MS
Curr Opin HIV AIDS; 2009 Nov; 4(6):513-7. PubMed ID: 20048719
[TBL] [Abstract][Full Text] [Related]
12. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
[TBL] [Abstract][Full Text] [Related]
13. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Visseaux B; Charpentier C; Hurtado-Nedelec M; Storto A; Antoine R; Peytavin G; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
Antimicrob Agents Chemother; 2012 Jan; 56(1):137-9. PubMed ID: 22064539
[TBL] [Abstract][Full Text] [Related]
14. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
Armand-Ugón M; Moncunill G; Gonzalez E; Mena M; Ballana E; Clotet B; Esté JA
J Antimicrob Chemother; 2010 Mar; 65(3):417-24. PubMed ID: 20067983
[TBL] [Abstract][Full Text] [Related]
15. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of viral entry.
Melby T; Westby M
Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
18. Novel agents for the treatment of HIV-2 infection.
Peterson K; Rowland-Jones S
Antivir Ther; 2012; 17(3):435-8. PubMed ID: 22301192
[TBL] [Abstract][Full Text] [Related]
19. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
[TBL] [Abstract][Full Text] [Related]
20. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
